MARKET

VCEL

VCEL

Vericel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.69
+2.14
+4.32%
Closed 16:19 09/17 EDT
OPEN
49.88
PREV CLOSE
49.55
HIGH
51.83
LOW
49.53
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
68.94
52 WEEK LOW
17.78
MARKET CAP
2.41B
P/E (TTM)
343.46
1D
5D
1M
3M
1Y
5Y
Vericel to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13th, 2021
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a virtu...
GlobeNewswire · 09/08 12:30
S&P, NASDAQ Begin Week with Another Session of Record Highs
S&P, NASDAQ Begin Week with Another Session of Record Highs
Zacks · 08/31 13:15
BRIEF-Vericel Corp Entered Into A Sales Agreement With Svb Leerink Llc
reuters.com · 08/27 21:53
--SVB Leerink Adjusts Vericel's Price Target to $62 from $67, Keeps Outperform Rating
MT Newswires · 08/05 11:53
Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/04 13:45
Vericel EPS in-line, beats on revenue; raises guidance
Vericel (NASDAQ:VCEL): Q2 GAAP EPS of -$0.08 in-line. Revenue of $39.52M (+97.5% Y/Y) beats by $2.74M. Gross margin of 68%, compared to 57% in Q2 2020. Non-GAAP adjusted EBITDA of
Seekingalpha · 08/04 12:10
Vericel Q2 EPS $(0.08), Inline, Sales $39.52M Beat $36.67M Estimate
Vericel (NASDAQ:VCEL) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 55.56 percent increase over losses of $(0.18) per share from the same period last year. The
Benzinga · 08/04 12:09
BRIEF-Vericel Reports Second Quarter 2021 Results And Raises Full-Year 2021 Revenue Guidance
reuters.com · 08/04 12:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VCEL. Analyze the recent business situations of Vericel through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VCEL stock price target is 65.04 with a high estimate of 68.00 and a low estimate of 62.00.
EPS
Institutional Holdings
Institutions: 287
Institutional Holdings: 62.16M
% Owned: 133.29%
Shares Outstanding: 46.63M
TypeInstitutionsShares
Increased
69
5.73M
New
35
636.03K
Decreased
82
3.20M
Sold Out
35
1.10M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Robert Zerbe
President/Chief Executive Officer/Director
Dominick Colangelo
Chief Financial Officer/Chief Accounting Officer
Joseph Mara
Chief Operating Officer
Michael Halpin
Vice President/General Counsel/Secretary
Sean Flynn
Other
Jonathan Hopper
Independent Director
Steven Gilman
Independent Director
Heidi Hagen
Independent Director
Kevin Mclaughlin
Independent Director
Alan Rubino
Independent Director
Paul Wotton
Independent Director
Lisa Wright
No Data
About VCEL
Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Webull offers kinds of Vericel Corp stock information, including NASDAQ:VCEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCEL stock methods without spending real money on the virtual paper trading platform.